Delaware Supreme Court agrees to hear GSK's Zantac appeal, leading to a 4% stock increase.
GSK stock prices rose after the Delaware Supreme Court agreed to hear their appeal in the Zantac case. The case involves allegations of carcinogenic impurities in Zantac and generic versions, leading to recalls and scrutiny. The court's decision to hear the appeal may influence ongoing litigation and attract investor attention. GSK shares increased 4% following the favorable ruling.
August 28, 2024
87 Articles